Session 3: Enabling biotech HIV vaccine R&D
The aim of this webinar is to highlight how biotech innovators are advancing vector engineering, nucleotide/viral platforms, small-scale manufacturing, and translational development including clinical studies. Identify enabling needs and collaboration opportunities across the entire HIV vaccine ecosystem.
Organized by the Global HIV Vaccine Enterprise and CPP Vaccine Industry Group
Audience: Open to the public, special invitation to CPP Cure and Vaccine members
